Double-Targeted immune cells take aim at Hard-to-Treat blood cancers
NCT ID NCT05436496
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD70, found on certain B cell cancers. The treatment involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing them back into the body. The study aims to see if this approach is safe and effective for people with B cell malignancies that have come back or not responded to standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bi-4SCAR CD19/70 T cells
What this could lead to
If successful, this could provide a new treatment option for patients with B cell cancers that have not responded to other therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the therapy may not work for everyone and could cause side effects like cytokine release syndrome or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••